Biotech psychedelics researcher and developer Silo Pharma Inc. SILO announced its topically-administered proprietary ketamine obtained a positive outcome in a recent preclinical study.
The trial has then proven the combination of Silo’s ketamine together with Zylo’s delivery system to yield positive results in reducing neuropathic nerve pain in a small animal study.
This data is extremely promising for patients suffering from fibromyalgia and rheumatoid arthritis,” CEO Eric Weisblum said.
“These positive results of our study show that Silo is able to successfully formulate and deliver ketamine topically at reduced dosage to achieve its endpoint of pain reduction. "
More specifically, ketamine was responsible for reducing mechanical allodynia and hyperalgesia at both pre and post-dosing time points, while mechanical hyperalgesia was reduced on day seven at the pre-dose time point. It should also be considered that the dosing was provided via a patent-protected delivery system with Silo’s partner Zylo Therapeutics.
Weisblum further added that “day seven and day nine scores averaged zero (no erythema or swelling present) for all groups, which bodes extremely well for our planned toxicology study.”
More On Allodynia And Hyperalgesia
Silo Pharma works towards developing treatments for people suffering from PTSD, Parkinson’s disease and rare neurological disorders. In this sense, the company’s most recent trial measured the effect of ketamine on two conditions related to pain sensitivity.
The NIH defines allodynia as “pain due to a stimulus that does not normally provoke pain.”
It is a condition on its own and may be found—as a symptom—in certain neurological disorders as well. An example would be a light feather touch causing pain rather than just sensation.
While they are both neuropathic diseases and can coexist, hyperalgesia is defined as “an exaggerated response from a normally painful stimulus.” This increased sensitivity to pain (sometimes “hypersensitivity”) or enhanced intensity of pain sensation is thought to be likely caused by damages in nociceptors or peripheral nerves.
Image by PublicDomainPictures from Pixabay
Edge Rankings
Price Trend
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Cannabis is evolving—don’t get left behind!
Curious about what’s next for the industry and how to stay ahead in today’s competitive market?
Join top executives, investors, and industry leaders at the Benzinga Cannabis Capital Conference in Chicago on June 9-10. Dive deep into market-shaping strategies, investment trends, and brand-building insights that will define the future of cannabis.
Secure your spot now before prices go up—this is where the biggest deals and connections happen!